[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555473":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":19,"id":49,"slug":19,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention arm","EXPERIMENTAL","second haploidentical stem cell transplantation",[13],"Other: second allogeneic stem cell transplantation",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"second allogeneic stem cell transplantation","1. Change another donor if possible\n2. Conditioning regimen: fludarabine (30mg\u002Fm2\u002Fday, days -6 to -2 )\u002Fcyclophosphamide (1g\u002Fm2\u002Fday, days -5 to -4)\u002Frabbit antithymocyte globulin (1.5mg\u002Fkg\u002Fday, days -4 to -2)\n3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng\u002Fml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg, +1d, +8d, +15d)",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Xiao-Jun Huang, M.D.","Institute of Hematology, Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Yu-qian Sun, M.D.","CONTACT","+86-10-88324577","sunyuqian83@hotmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Beijing","Beijing Municipality","100044","China",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"type":24,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Xiao-Jun Huang","Prof.","100555473",false,"NCT06512545","Modified Second Haplo-transplantation for Graft Failure","Second Haploidentical Transplantation with Modified Regimen for Graft Failure After the First Allogeneic Stem Cell Transplantation","Inclusion Criteria:\n\n* 1.Primary disease: hematological malignancies(AML, CML, MDS, lymphoma, etc.); 2.Graft failure after first allogeneic stem cell transplantation; 3.Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.\n\nExclusion Criteria:\n\n* 1\\. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\\\u003C50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\\>2; 5. Expected life time\\\u003C30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,","ALL","14 Years",{"count":58,"type":59},12,"ESTIMATED","INTERVENTIONAL",[62],"NA","Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. We previously reported encouraging results with a novel Flu\u002FCy regimen. However, there are still around 20% patients developed delayed platelet recovery. We designed a modified regimen to further improve the hematopoietic reconstitution after second transplantation. This prospective, single-arm study aims to investigate the safety and efficacy of this modified regimen.",[65,66],"Graft Failure","Stem Cell Transplant Complications","2024-11-26",{"date":69,"type":70},"2024-11-29","ACTUAL",{"date":72,"type":70},"2024-07-01",{"date":74,"type":59},"2026-06-30",{"name":5,"class":6},1]